JAK

Janus kinases (JAKs), belonging to a distinct family of tyrosine kinases, are non-receptor tyrosine kinases that transduce signals of cytokine receptors via diverse signal transduction pathways. Mammalian JAK family consists of four structurally similar members, JAK1, JAK2, JAK3 and Tyrosine kinase 2 (TYK2), which are characterized by containing seven JAK homology (JH) domains. The presence of JH1 and JH2 domains is the most intriguing feature of JAK proteins. JH1 domain is the main catalytic domain; while JH2 is usually considered as a catalytically inactive pseudokinase domain. However, results of recent studies have shown that JH2 acts as a dual-specificity protein kinase to phosphorylate two regulatory sites (Ser523 and Tyr570) in JAK2.

Products for JAK

dummy(1)

Cat.No. 产品名称 Information
GC37846 Tyk2-IN-7 Tyk2-IN-7 (Compound 48) 是 TYK2 JH2 抑制剂，与 TYK2 JH2 结构域结合，IC50 和 Ki.app 分别为 0.00053 μM 和 0.00007 μM。Tyk2-IN-7 (Compound 48) 是常规 TYK2 正构抑制剂的高选择性替代，抑制 TYK2/JAK1/JAK2 激酶结构域。Tyk2-IN-7 (Compound 48) 抑制小鼠 IL-12 诱导的 IFNγ 药效学模型中以及抑制在 IL-23 和 IL-12 依赖性小鼠结肠炎模型中的功效。
GC37847 Tyk2-IN-8 Ropsacitinib (PF-06826647, Tyk2-IN-8, compound 10) is a selective and orally administered inhibitor of tyrosine kinase 2 (TYK2) with IC50 of 17 nM for binding to TYK2 catalytically active JH1 domain. PF-06826647 (Tyk2-IN-8, compound 10) also inhibits JAK1 and JAK2 with IC50 of 383 nM and 74 nM, respectively. PF-06826647 (Tyk2-IN-8, compound 10) is used in the treatment of psoriasis (PSO).
GC19368 Upadacitinib

乌帕替尼; ABT-494
Upadacitinib是一种高效、口服并可逆的选择性 Janus激酶 1 (JAK1) 抑制剂，IC₅₀值为0.043μM_。
GC67867 VVD-118313 VVD-118313 (compound 5a) 是一个有效的选择性 JAK1 抑制剂。VVD-118313 靶向异构体限制性变构半胱氨酸 (C817)，阻断 JAK1 依赖的反式磷酸化和细胞因子信号。VVD-118313 可用于癌症的研究。
GC15589 WHI-P154

2-溴-4-(6,7-二甲氧基喹唑啉-4-基氨基)苯酚
A JAK3 inhibitor
GC15956 WHI-P97

4-(3',5'-二溴-4-羟基苯基)氨基-6,7-二甲氧基喹唑啉,WHI-P-97;WHI P97
WHI-P97 是一种有效的选择性 JAK-3 抑制剂。
GC15980 WP1066

(2E)-3-(6-溴-2-吡啶基)-2-氰基-N-[(1S)-1-苯基乙基]-2-丙烯酰胺

An inhibitor of STAT3
GC14327 XL019

XL-019;XL 019
A potent, bioavailable JAK2 inhibitor
GC14245 ZM 39923 HCl

3-[异丙基(苄基)氨基]-1-(2-萘基)-1-丙酮盐酸盐
A potent inhibitor of JAK3
GC15125 ZM 449829

2-萘乙烯基酮
An inhibitor of JAK3
GC37971 ZM39923 A potent inhibitor of JAK3
GC62112 Zotiraciclib Zotiraciclib (SB1317; TG02) is a novel small molecule potent CDK/JAK2/FLT3 inhibitor, emerged with potent CDK (IC50 against CDKs 1, 2 and 9 = 9, 5 and 3 nM, respectively), FLT3 (IC50 = 19 nM) and JAK2 (IC50 = 19 nM) potency.